Abstract
The prevalence of autism in Denmark has been increasing, reaching 1.65% among 10-year-old children and similar trends are seen elsewhere. Although there are several factors associated with autism, including genetic, environmental and prenatal factors, the molecular etiology of autism is largely unknown. Metabolomics has emerged as a tool to measure small molecules that reflect genetic, gut microbiome and dietary intake variations. Here, we apply untargeted metabolomics to over 1400 neonatal dried bloods spots, including neonates who later are diagnosed with autism and matching controls. Overall, we detect underlying molecular perturbations that precede autism related to metabolism of amino acids, acylcarnitines and peptides. In particular the cyclic dipeptide cyclo-leucine-proline and the carnitine-related 5-aminovaleric acid betaine (5-AVAB), were associated with an increased probability for autism. Analysis of genetic and dietary data in over 7000 adults revealed that 5-AVAB was associated with increased habitual dietary intake of dairy and with variants SLC22A5, coding for a transmembrane carnitine transporter protein involved in controlling intracellular carnitine levels. We identify 5-AVAB as a novel and potentially modifiable early biomarker for autism that may influence carnitine homeostasis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was funded by the Lundbeck Foundation through The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), grant number R248-2017-2003-Period III: 1 March 2018 to 28 February 2021; R155-2014-1724: Period II: 1 March 2015 to 28 February 2018; R102-A9118: Period I: 1 March 2012 to 28 February 2015. This research has been conducted using the Danish National Biobank resource supported by the Novo Nordisk Foundation. Some of the computing for this project was performed on the GenomeDK cluster. We would like to thank GenomeDK and Aarhus University for providing computational resources and support that contributed to these research results.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The neonatal metabolomics study was conducted according to the principles of the Declaration of Helsinki and approved by the Danish Ethics Committee(1-10-72-287-12) and the ethics committee of Lund University approved the study protocols for MOS (DNR 2012/594) and MDC (DNR2009/633).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The data underlying this study are not publicly available due to the Danish Data Protection Act and European Regulation 2016/679 of the European Parliament and of the Council (GDPR) that prohibit distribution of personal data.The data are available from the corresponding authors upon reasonable request and under a data transfer and collaboration agreement.
